Vital Signs - Impact of 'Intended Use' On New Diagnostics

Vital Signs - Impact of 'Intended Use' On New Diagnostics

 

RELEASE DATE
22-Dec-2008
REGION
North America
Research Code: 9561-00-7E-00-00
SKU: HC00557-NA-MR_04029
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00557-NA-MR_04029

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on December 22, 2008, provides an strategic overview of the impact of intended use on new clinical diagnostics. Additionally, a company spotlight is provided for InfraReDx, an emerging medical diagnostics company. Reimbursement and regulatory news from the FDA is also provided for the week of December 8, 2008.

Table of Contents

Related Research
This issue of Vital Signs, released on December 22, 2008, provides an strategic overview of the impact of intended use on new clinical diagnostics. Additionally, a company spotlight is provided for InfraReDx, an emerging medical diagnostics company. Reimbursement and regulatory news from the FDA is also provided for the week of December 8, 2008.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-7E-00-00
Is Prebook No